FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as ... has approvals in cardiovascular disease and chronic kidney disease and is looking at various other indications ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

Eli Lilly and Novo Nordisk have been competing ... including chronic kidney disease. Similarly, tirzepatide has been approved for type 2 diabetes under the name Mounjaro and for obesity under ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

Eli Lilly started 2024 on a strong note but struggled during the second half of the year. The drugmaker dealt with several ...

#Eli_Lilly's #Zepbound ... obstructive sleep apnea. Tirzepatide is being investigated for four additional indications, including cardiovascular risk factors, chronic kidney disease, and metabolic ...